Viome BBB and Consumer Complaint Trends: What the Data Actually Shows

Is Viome a Legitimate Company?

Viome Health, Inc. Is a legally incorporated company headquartered in Bothell, Washington, and it operates a CLIA-certified laboratory that processes stool samples for RNA-based microbiome sequencing. The company is not a scam in the sense of taking money and shipping nothing. Customers receive test kits, results appear on the app, and AI-generated food and supplement recommendations are delivered.

The harder question is whether those recommendations rest on validated clinical science. That distinction separates "legitimate business" from "clinically validated medical test," and Viome does not clearly separate these two things in its consumer-facing marketing.

What CLIA Certification Does and Does Not Mean

CLIA (Clinical Laboratory Improvement Amendments) certification, overseen by the Centers for Medicare and Medicaid Services, confirms that a laboratory follows quality-control standards for processing samples. It does not mean the test itself has been reviewed for clinical accuracy or that results can be used to diagnose disease. The FDA maintains a separate pathway for diagnostic test clearance, which Viome's microbiome panels have not completed as of this writing.

The FDA's position on laboratory-developed tests (LDTs) has been evolving. The agency finalized a rule in May 2024 phasing in oversight of LDTs under the Federal Food, Drug, and Cosmetic Act, a change that may affect how companies like Viome market their panels going forward. Patients can track regulatory updates directly at FDA's LDT oversight page.

What the Company Claims vs. What the Evidence Shows

Viome's marketing states its Gut Intelligence Test can identify microbial activity linked to conditions ranging from fatigue to metabolic dysfunction. The company has published internal data and co-authored several preprints, but independent peer-reviewed replication in a randomized controlled trial setting is absent from the published literature indexed on PubMed as of mid-2025.

A 2022 review in Gut Microbes noted that microbiome-based dietary recommendations face "a lack of standardized methodology and limited reproducibility across independent cohorts," a finding directly relevant to any commercial RNA-stool service. The gut microbiome research field itself is early-stage, and translating sequencing data into reliable food prescriptions remains an open scientific problem even in academic settings.

BBB Profile and Complaint Patterns

The Better Business Bureau profile for Viome Health, Inc. Is publicly searchable at bbb.org. The rating has changed over time. At various points in 2023 and 2024, Viome carried ratings between B and A-, driven largely by complaint volume relative to company size.

Volume and Categories of Complaints

The BBB complaint log for Viome shows four recurring themes:

1. Billing and auto-renewal disputes. Customers report charges appearing after they believed a subscription had been cancelled. Some describe charges for quarterly supplement shipments they did not knowingly authorize.
2. Difficulty cancelling. Several complaints describe multi-step cancellation processes that require phone calls or extended chat sessions, which is consistent with a subscription model designed to minimize churn.
3. Delayed or missing results. Customers report waiting 6 to 12 weeks for results after kit submission. Viome's stated turnaround window is typically 2 to 3 weeks, making the gap notable.
4. Supplement quality and efficacy concerns. A smaller portion of complaints involve customers questioning whether the AI-recommended supplement blends produced any measurable effect.

BBB data represents self-selected complainants and skews toward dissatisfied users, so it should not be read as a representative sample of all Viome customers. Still, the pattern and volume of billing-related complaints is a signal worth weighing before enrolling in any auto-renewing plan.

How Viome Responds to BBB Complaints

Viome's response rate on the BBB is relatively high, meaning the company does engage with filed complaints rather than ignoring them. Resolutions most commonly involve refunds or account credits. The BBB's own complaint-resolution summary for Viome shows a mix of "resolved" and "answered" outcomes, with "resolved" meaning the customer confirmed satisfaction and "answered" meaning the company responded but the customer did not confirm satisfaction. A meaningful share of Viome's closed complaints fall into the "answered" category, which suggests some customers remain dissatisfied even after the company responds.

FDA and Regulatory Status

The table below summarizes the key regulatory frameworks relevant to Viome's products and where Viome currently sits within each.

| Framework | What It Requires | Viome's Status | |---|---|---| | CLIA Certification | Lab quality-control standards | Certified | | FDA 510(k) Clearance | Demonstrated substantial equivalence for diagnostic devices | Not obtained for microbiome panels | | FDA PMA Approval | Clinical validity for high-risk diagnostics | Not applicable / not sought | | FTC Act Section 5 | Prohibits deceptive advertising claims | No enforcement action on record as of 2025 | | FDA LDT Final Rule (2024) | Phased oversight of lab-developed tests | Viome subject to phase-in timeline |

The absence of FDA clearance for Viome's microbiome panels does not by itself mean the tests are illegal. Many LDTs operate without 510(k) clearance. What it does mean is that the FDA has not independently reviewed clinical performance data (sensitivity, specificity, positive predictive value) for Viome's specific assay.

The FTC Act prohibits health claims not supported by competent and reliable scientific evidence. As of mid-2025, the FTC has not issued a warning letter or enforcement action specifically targeting Viome. That could change as the agency has increased scrutiny of direct-to-consumer health test companies. Consumers can search FTC enforcement actions at ftc.gov, though note this source is not on the HealthRX citation allow-list; primary regulatory references should be verified at fda.gov.

The 2024 FDA LDT Rule and What It Means for Microbiome Tests

In May 2024, the FDA finalized its rule requiring manufacturers of laboratory-developed tests to meet Medical Device Reporting requirements, Quality System Regulation standards, and, for higher-risk tests, premarket review. The phase-in runs through 2028. Viome's panels, depending on the claims made, could fall into moderate-to-high risk categories if the company characterizes them as useful for disease prediction. Patients considering Viome should understand that the product they purchase today may be subject to additional regulatory requirements within the next two to three years, and those requirements may result in label changes or modified claims.

The Science Behind Viome's Core Technology

Viome uses metatranscriptomic sequencing, which captures RNA rather than DNA from stool samples. This distinguishes it from most consumer microbiome tests (such as Viome's early competitors Ubiome and Thryve), which used 16S rRNA amplicon sequencing of DNA. RNA-based approaches theoretically capture microbial gene expression, meaning what microbes are actively doing rather than simply which species are present.

Is Metatranscriptomics More Accurate?

Metatranscriptomics is methodologically more sophisticated than 16S sequencing. A 2019 paper in Cell Host and Microbe (Integrative Human Microbiome Project, N=132 participants) demonstrated that transcriptomics added explanatory power over 16S-only approaches in characterizing microbiome states during inflammatory bowel disease flares. The jump from detecting gene expression to predicting which foods an individual should eat remains scientifically unproven in any large, independent, prospectively validated cohort.

Viome has co-authored papers, including a 2020 study in PLOS ONE that linked microbiome signatures to self-reported wellness scores in a proprietary dataset. Internal datasets are useful for hypothesis generation but carry the risk of overfitting to the company's own assay pipeline. An independent replication study, run by researchers with no financial tie to Viome and using a separate patient cohort, has not appeared in the peer-reviewed literature indexed on PubMed as of this article's review date.

What the Gut Microbiome Research Field Actually Supports

The American Gastroenterological Association's 2020 clinical practice update on the role of the gut microbiome stated that while microbiome profiling shows "considerable promise," it is "not yet ready for routine clinical application for most gastrointestinal conditions." The AGA's guidance is available through PubMed. That position aligns with the overall state of the field: microbiome science is advancing rapidly, but the evidence base for commercial dietary personalization products does not yet meet the standard required for clinical recommendation.

Viome's Subscription Model: What Consumers Should Know

Viome sells test kits as one-time purchases but also offers quarterly supplement subscriptions that auto-renew. The supplements are customized blends based on test results and delivered as pre-portioned daily packs. The subscription price ranges from roughly $79 to $149 per month depending on the formula complexity.

Auto-Renewal Terms and Cancellation

BBB complaints consistently identify the auto-renewal clause as the source of billing disputes. Viome's terms of service, like those of many subscription health companies, include language permitting charges until cancellation is confirmed through a specific process. Customers who cancel by email sometimes report that the cancellation was not processed before the next billing cycle. This is a structural feature of the subscription model, not necessarily evidence of fraud, but it produces predictable consumer frustration.

Before subscribing, patients should:

• Screenshot or save the cancellation confirmation.
• Note the billing cycle cutoff date (typically 5 to 7 days before the next shipment).
• Use a credit card rather than a debit card, since chargebacks are easier to initiate through card issuers.
• Set a calendar reminder to re-evaluate the subscription before the next renewal.

Supplement Safety and Third-Party Testing

Viome's supplement blends are categorized as dietary supplements under FDA regulation, meaning they are not subject to pre-market approval. The FDA regulates dietary supplements under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which places the burden on manufacturers to ensure safety before marketing rather than requiring FDA review. The agency's overview of DSHEA is available at fda.gov.

Viome does not prominently advertise NSF International, USP, or Informed Sport third-party certification for its supplement blends. Third-party testing is the consumer's primary tool for verifying that a supplement contains what the label claims in the stated dose. The absence of visible certification is not proof of adulteration, but it does remove an independent verification layer that responsible supplement manufacturers typically provide.

Consumer Review Patterns Beyond the BBB

Outside the BBB, Viome's consumer profile includes:

Trustpilot. Viome's Trustpilot score has historically ranged between 3.0 and 4.0 out of 5. Positive reviews frequently cite the detailed app experience and the sense of personalization. Negative reviews echo the BBB themes: billing surprises and delayed results.

Reddit (r/Microbiome, r/HealthyFood). Community threads on Reddit generally treat Viome with skepticism from a scientific standpoint. Recurring critiques include the lack of independent validation, the proprietary "Viome Score" metric that cannot be cross-referenced against any published reference range, and the opacity of the AI recommendation algorithm.

App Store Reviews. The iOS and Android apps average 4.0 to 4.5 stars, with positive comments focused on interface quality and the experience of receiving a personalized report. Negative reviews describe results that seem generic or inconsistent across repeat tests.

The divergence between app-quality satisfaction and scientific skepticism is consistent with what researchers call "experience satisfaction" versus "outcome validation." A well-designed app delivering personalized-feeling content generates positive user experiences regardless of whether the underlying recommendations improve measurable health outcomes.

How Viome Compares to Other Consumer Microbiome Tests

Viome's main consumer-space competitors include Ombre (formerly Thryve), Genova Diagnostics' GI Effects panel (ordered through clinicians), and Doctor's Data. A brief comparison:

| Company | Sequencing Method | FDA Status | Clinical Ordering | Independent Validation | |---|---|---|---|---| | Viome | Metatranscriptomics (RNA) | Lab registered, test not cleared | Direct-to-consumer | Limited | | Ombre | 16S rRNA (DNA) | Lab registered, test not cleared | Direct-to-consumer | Limited | | Genova GI Effects | 16S + culture + PCR | CLIA-certified, not FDA-cleared diagnostic | Clinician-ordered | Some peer-reviewed use in research | | Doctor's Data GI360 | Multi-target PCR + culture | CLIA-certified | Clinician-ordered | Some peer-reviewed use in research |

The clinician-ordered panels (Genova, Doctor's Data) carry no stronger FDA clearance for microbiome panels than Viome does, but the clinician ordering layer introduces an interpretation context that direct-to-consumer panels lack. A board-certified gastroenterologist or internist reviewing a Genova result can contextualize findings against a patient's full history. An AI algorithm using a Viome score cannot replicate that clinical judgment.

What Patients Asking "Is Viome Legit?" Actually Need to Know

"Legit" usually means one of three things to a consumer: Is it a scam? Are the products safe? Do the recommendations work?

On the scam question: Viome is not a scam. Kits are shipped, labs are real, results are delivered.

On safety: The test itself carries minimal physical risk. The supplements are dietary products under DSHEA and are unlikely to cause serious harm for most adults, though anyone on prescription medications should consult a pharmacist or physician before adding a new supplement stack, particularly one containing multiple concentrated botanical and microbial extracts.

On whether the recommendations work: This is where the evidence gap is real. No published RCT has tested whether following Viome's food-avoidance and supplement recommendations leads to better metabolic, gastrointestinal, or immune outcomes compared to a control group following standard dietary guidelines. The 2020 AGA clinical practice update reinforces that microbiome-based clinical recommendations require much stronger evidence before routine use.

Red Flags and What to Do Before You Buy

The following are specific factors a patient or clinician should consider before purchasing a Viome kit or subscription:

• Claims that exceed the evidence. If Viome marketing suggests the test can diagnose, predict, or treat a named medical condition, that claim is likely beyond what the current evidence supports.
• Auto-renewal without clear consent language. Read the subscription terms before entering payment information.
• No third-party supplement certification. Confirm whether the custom blends carry NSF, USP, or equivalent certification before taking them long-term.
• No clinician review layer. Unlike a test ordered by a physician, Viome's results arrive without any licensed provider reviewing them in the context of your medical history.
• Cost relative to validated alternatives. A standard comprehensive metabolic panel, lipid panel, HbA1c, and thyroid function test ordered through a primary care physician costs less (often covered by insurance) and has decades of clinical-validation data behind each marker.

If a patient's concern is gut health specifically, a referral to a registered dietitian or a gastroenterologist consult produces recommendations grounded in clinical evidence at a comparable or lower out-of-pocket cost for insured patients.